Health Plan News logo

Bradley Pharmaceuticals Low-Dose Estrogen Therapy Supported by Recent Medical Literature

Bradley Pharmaceuticals, Inc. (NYSE:BDY) reports a growing trend in medical literature and general media in support of low-dose estrogen replacement therapies and transdermal estradiol products. The most recent article appears in the March issue of Obstetrics and Gynecology, the journal of the American College of Obstetrics and Gynecology (ACOG). The ...

March 11th 2010
Tags: Healthcare Plan News Comments Off

Blue Cross Blue Shield of Michigan Foundation Wins Big at 2010 Wilmer Shields Rich Awards Program

The Blue Cross Blue Shield of Michigan Foundation earned two national awards for Excellence in Communications, one gold and one silver, in the 2010 Wilmer Shields Rich Awards Program. The awards, given by the Council on Foundations and the Communications Network, recognize important communication efforts that increase public awareness of ...
March 2nd 2010
Tags: Healthcare Plan News Comments Off

HealthPass Now Offering UnitedHealthcare’s Oxford Health Benefit Plans

HealthPass, a partnership between New York City, the New York Business Group on Health, and the health insurance industry, is now offering five of UnitedHealthcare's Oxford health insurance plans to employers. To qualify, the employers must have two to 50 eligible employees and be based in New York City or ...
March 2nd 2010
Tags: Healthcare Plan News Comments Off

Verizon Wireless’ Mobile Healthcare Solutions Let Hospitals and Clinics Streamline Communications and Access Critical Data

BASKING RIDGE, N.J., and ATLANTA, March 2 /PRNewswire/ -- Healthcare organizations ranging from large city hospitals to rural community health clinics can count on Verizon Wireless to deliver customized wireless solutions that allow caregivers the ability to utilize resources that enhance the patient experience. Representatives from Verizon Wireless, operator of ...
March 2nd 2010
Tags: Healthcare Plan News Comments Off

Enanta Nominates EDP-239 as Lead Development Candidate for NS5A HCV Inhibitor Program

WATERTOWN, Mass., March 2 /PRNewswire/ -- Enanta Pharmaceuticals, Inc. announced today the nomination of lead development candidate, EDP-239, from its NS5A hepatitis C virus (HCV) inhibitor program. EDP-239 has demonstrated picomolar potency against multiple genotypes of the virus and a preclinical pharmacokinetic profile amenable to once-a-day dosing. "Our NS5A inhibitor program ...
March 2nd 2010
Tags: Healthcare Plan News Comments Off

Abbott and Enanta Announce Advancement of Hepatitis C Collaboration

ABBOTT PARK, Ill. and WATERTOWN, Mass., March 2 /PRNewswire-FirstCall/ -- Abbott (NYSE:ABT) and Enanta Pharmaceuticals announced today the advancement of their Hepatitis C (HCV) collaboration into Phase 2 clinical trials. The trial will evaluate three HCV antiviral agents, including the investigational protease inhibitor ABT-450, part of the Abbott-Enanta collaboration, and ...

Search

The archives run deep. Feel free to search older content using topic keywords.

Browse by Category